Reata Pharma's bardoxolone an orphan drug for ADPKD

|About: Reata Pharmaceuticals, Inc. (RETA)|By:, SA News Editor

The FDA has granted orphan drug designation to Reata Pharmaceuticals' (NASDAQ:RETA) bardoxolone methyl (bardoxolone) for the treatment of autosomal dominant polycystic kidney disease (ADPKD).

Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved.

Subscribe for full text news in your inbox